Immuron Limited received A$1,121,885 R&D Tax Incentive for eligible activities conducted during the financial year ending June 30, 2025. This non-dilutive funding supports investment in growth of Hyper-Immune products sales and profitability while maintaining financial flexibility.
Key takeaways
Received A$1,121,885 R&D Tax Incentive on February 17, 2026
Incentive for FY ended June 30, 2025 at 43.5% of eligible R&D expenditure
Provides non-dilutive funding for sales and profitability growth
Planning growth in profitability of Hyper-Immune products net of increased selling & marketing investment
Targeting improvement in EBITDX (ex-R&D) in FY26 via cost reductions